Previous Close | 2.2700 |
Open | 2.2900 |
Bid | 2.1900 x 200 |
Ask | 2.2500 x 200 |
Day's Range | 2.1920 - 2.3400 |
52 Week Range | 0.8900 - 5.3300 |
Volume | |
Avg. Volume | 411,877 |
Market Cap | 56.944M |
Beta (5Y Monthly) | 0.34 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
In the trial, GT-02287 was found to be safe and well-tolerated at all dose levels, including the highest planned doses.
Biotech stocks are not for everyone, let’s make that perfectly clear. It’s challenging to invest in a field in which companies – particularly startups – can go for years without seeing a penny of revenue. While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get into too much trouble. Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and te